Related Experiment Video

Updated: Apr 28, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K

The current state and future prospects of chronic hepatitis C virus infection treatment

Christopher Moore1, Josh Levitsky

  • 1Section of Hepatology, Department of Medicine, Northwestern University, Chicago, IL, USA, christopher.moore@northwestern.edu.

Current Infectious Disease Reports
|June 5, 2014
PubMed

Insights

New Hepatitis C virus (HCV) therapies offer higher cure rates with fewer side effects. This review highlights sofosbuvir and simeprevir, alongside emerging treatments for chronic liver disease.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection is a major cause of chronic liver disease.
  • Previous HCV therapies had high nonresponse rates and significant side effects.
  • Recent advancements have introduced more effective and tolerable treatments.

Purpose of the Study:

  • To review the efficacy and safety of newly approved HCV therapies.
  • To discuss key clinical studies supporting the use of these new treatments.
  • To provide an overview of novel antiviral therapies in development.

Main Methods:

  • Review of clinical trial data for sofosbuvir and simeprevir.
  • Analysis of treatment outcomes, including cure rates and side effect profiles.
  • Examination of emerging antiviral agents in advanced testing phases.

Main Results:

  • Sofosbuvir (NS5b polymerase inhibitor) and simeprevir (NS3/4A protease inhibitor) show improved cure rates.
  • These newer therapies exhibit a more favorable side effect profile compared to older regimens.
  • Advanced-stage novel antiviral therapies are also demonstrating promise.

Conclusions:

  • Sofosbuvir and simeprevir represent significant progress in HCV treatment.
  • These agents offer better tolerability and efficacy across various HCV populations.
  • The landscape of HCV treatment is rapidly evolving with promising new therapies.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
80
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
22
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
561
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382